mRNA-Driven iPSC Reprogramming Service

Precision Non-Viral Reprogramming for Transformative Research

Creative Biolabs offers an end-to-end mRNA-driven iPSC reprogramming service, which allows you to expedite your discovery with iPSC of high quality. We harness safe, clinically relevant but non-integrating mRNA technology to produce iPS cells within 16 days. We are the only company that can deliver functionally superior iPSCs with no genomic integration and no viral contamination for disease modeling, drug screening, and regenerative mechanism studies.

Core Technology Innovations - Engineered mRNA & Delivery System

• Stealth mRNA Constructs: Proprietary 5'/3' UTR designs and codon optimization suppress innate immune activation, enabling sustained expression of reprogramming factors without compromising cell viability.
• Modular Co-Delivery: Optional integration of microRNAs or gene editing components enhances somatic gene silencing or mutation correction during reprogramming.
• Automated Workflow: Standardized daily transfections and optimized media achieve >1% efficiency, significantly outperforming viral methods in speed and reliability.

Enhanced Research Applications - Exclusively for preclinical investigation

• Patient-Specific Disease Modeling: Generate iPSCs from neurodegenerative (e.g., Parkinson's, ALS) or genetic disorder cohorts to dissect pathogenic mechanisms and identify therapeutic targets.
• High-Throughput Drug Screening: Differentiate iPSCs into neurons or cardiomyocytes for toxicity/efficacy profiling in automated platforms.
• Gene Editing-Edited Model Generation: Combine mRNA reprogramming with gene editing machinery (e.g., nuclease mRNA/sgRNA) co-delivery to introduce disease-associated mutations or reporter genes.
• Immune Cell Differentiation: Engineer iPSC-derived T/NK cells under xeno-free conditions for tumor-immune interaction studies.

Featured Services

Integrated iPSC Solutions for Transformative Research

Creative Biolabs delivers end-to-end solutions for creating research-grade-induced pluripotent stem cells (iPSCs) using non-integrating mRNA technology. Our platform expresses reprogramming factors (OCT4, KLF4, SOX2, GLIS1) as engineered mRNA strands, enabling:

• Zero genomic footprint without viral intermediates or host genome integration
• Single-transfection efficiency for accelerated colony formation
• Controllable expression kinetics via media optimization

Fig.1 mRNA-Driven iPSC Reprogramming Service and Quality Assurance System.

Related mRNA Services

Advantages of mRNA-Driven iPSC Reprogramming Technology

mRNA-driven iPSC reprogramming technology provides you with significant advantages over viral and non-viral methods in research applications. The main advantages are as follows:

• Superior Safety and Non-Integrating Nature:

Non-integrating method of virus causes risk of genomic integration and insertional mutagenesis, whereas mRNA-mediated reprogramming uses synthetic mRNA, which does not integrate into the genome or carry the viral components. Thus, there is no safety concerns, no need for long-term viral removal.

• Super-Fast and High-Efficiency:

mRNA-based reprogramming generates iPS cells in 16 days, faster than viral reprogramming or protein reprogramming. It achieves a reprogramming efficiency greater than 1%, which is much higher than viral reprogramming and protein reprogramming.

• Simple Workflow and High Scalability:

mRNA-based reprogramming avoids laborious steps including viral selection, repeated passaging, or integration test of other reprogramming methods. With optimized medium and daily transfection, it supports fully automated and scalable iPSC generation for high-throughput disease modeling and drug screening.

• Biological Relevance:

By maintaining the native epigenetic landscape and avoiding ex vivo manipulation artifacts, mRNA-based iPSCs provide more accurate disease modeling and regenerative biology.

Partner with Creative Biolabs

Creative Biolabs' end-to-end mRNA-driven iPSC reprogramming service couples the non-integrating mRNA technology with specific differentiations. Our platform empowers researchers to overcome traditional limitations of viral reprogramming through:

• Native epigenetic preservation: Maintains endogenous gene regulation patterns
• Scalable workflows: Automated processing for high-throughput studies

Core Capabilities

• Cell source flexibility: Skin, blood, urine-derived samples
• Multi-omics validation: proteomic, and functional phenotyping
• Xeno-free differentiation: Neurons, cardiomyocytes, immune cells

Initiate Your Project

Partner with our stem cell specialists to:

• Specify donor cell type and disease model
• Design gene editing integration or differentiation requirements
• Receive a customized project roadmap

Contact us to request validation data, case studies, or feasibility assessments.

FAQs

Featured mRNA Products

Reference

1. Tavares-Marcos, Carlota, Magda Correia, and Bruno Bernardes de Jesus. "Telomeres as hallmarks of iPSC aging: a review on telomere dynamics during stemness and cellular reprogramming." Ageing Research Reviews (2025): 102773. Distributed under Open Access license CC-BY 4.0, without modification. https://doi.org/10.1016/j.arr.2025.102773